At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating dasatinib for Extensive Stage Small Cell Lung Cancer and 2 related conditions. Completed, enrolled 44 participants across 1 site.
Detailed Summary
This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionFeb 2009
Study CompletionApr 2013
TodayJul 2026
First PostedMay 7, 2007
Enrollment StartApr 1, 2007
Primary CompletionFeb 1, 2009
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.2 years ago
Interventions
dasatinibdrug
Given PO